Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

BTG Gets EU Nod For Lemtrada

By Edison Stock MarketsJul 01, 2013 07:10AM ET
www.investing.com/analysis/btg-gets-eu-nod-for-lemtrada-173575
BTG Gets EU Nod For Lemtrada
By Edison   |  Jul 01, 2013 07:10AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
The positive European regulatory opinion on Lemtrada (multiple sclerosis therapy) points to EU approval in Q313 and potential launch shortly thereafter. The recommended indication represents, in our view, a best case scenario for BTG (BGC:L) and partner Sanofi (SNY). Separately, an FDA decision on Lemtrada is expected late-2013. With the positive EU opinion adding 10p to our risk-adjusted DCF, our new fair value for BTG is 510p.
BTG
BTG

Positive EU regulatory opinion on Lemtrada…
The European regulator (CHMP) has recommended that Lemtrada should be approved to treat multiple sclerosis (MS). As a reminder, Lemtrada is partnered with Sanofi/Genzyme and, we estimate, BTG receives a c 6% gross (c 3% net) royalty on global sales until September 2017. The recommended indication ‘adult patients with relapsing remitting MS (RRMS) with active disease defined by clinical of imaging features’ and dosing ‘two annual treatment courses’ is consistent with Lemtrada’s use in Phase III studies. This represents, in our view, a best case scenario given the lack of other restrictions to use in RRMS patients. Despite this, we expect initial Lemtrada use in more severe patients given the availability of other MS therapies and the potential side effects (autoimmune thyroid disorders).

…Should trigger formal approval in Q313
We anticipate formal EU approval in Q313 and potential launch shortly thereafter. Edison sees Lemtrada sales achieving $750m (c 40% in EU) in 2016 (BTG’s last full year of royalty entitlement) with BTG receiving gross royalties of £29m (£14.5m net) in FY17. However, the key unknown is pricing - Sanofi is faced with an unusual pricing issue given the drug’s infrequent dosing (two courses only) rather than chronic use. Separately, the FDA recently extended the review cycle by 3 months, which means a US approval decision is expected late 2013.

Valuation: Fair value of 510p per share
Following the CHMP opinion, we have raised our probability of success on EU Lemtrada sales to 100% (from 80%). We now value BTG at £1.83bn, or 510p per share, based on a probability-weighted, sum-of the-parts (SOTP) DCF analysis. We value the business segments at £2.06bn, deduct R&D (£208m) and capex (£43m) costs and add net cash (£28m) to arrive at our fair value. Our fair value of 510p per share offers c 40% upside to the current share price and, moreover, is underpinned by a value of 341p for marketed assets. This implies downside protection and potential if the pipeline fails to achieve key data and regulatory milestones.

To Read the Entire Report Please Click on the pdf File Below.


BTG Gets EU Nod For Lemtrada
 

Related Articles

BTG Gets EU Nod For Lemtrada

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email